TMCnet News
Research and Markets: Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H1 2014 ReportDUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/ntfn59/familial) has announced the addition of the "Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H1 2014" report to their offering. 'Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia). Scope - A snapshot of the global therapeutic scenario for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia). - A review of the Familial Hypercholesterolemia (Type II Hyperlipproteinemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Therapeutics Assessment Drug Profiles anacetrapib - Drug Profile evolocumab - Drug Profile CER-001 - Drug Profile Gene Therapy To Activate LDL Receptor For Familial Hypercholesterolemia - Drug Profile Antisense Oilgonucleotides to Inhibit ApoB100 for Familial Hypercholesterolemia - Drug Profile BSN-272 - Drug Profile Featured News & Press Releases Appendix Companies Mentioned Merck & Co., Inc. ReGenX Biosciences, LLC Cerenis Therapeutics SA Amgen Astellas BioPharma K.K. Biospherics.net Incorporated For more information visit http://www.researchandmarkets.com/research/ntfn59/familial About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
|